- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01945021
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
February 3, 2021 updated by: Pfizer
Phase II, Open Label, Single Arm Study of the Efficacy and Safety of Crizotinib in East Asian Patients With Advanced ALK-Negative NSCLC Harboring a Translocation or Inversion Involving the c-ROS Oncogene (ROS1) Locus
To assess treatment effectiveness and safety of oral crizotinib administered to East Asian patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a ROS1 positive gene mutation (translocation or inversion) and confirmed negative for an ALK mutation
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
129
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230022
- The First Affiliated Hospital of Anhui Medical University, Department of Medical Oncology
-
-
Beijing
-
Chaoyang District, Beijing, China, 100021
- Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
-
Dongcheng District, Beijing, China, 100700
- The Military General Hospital of Beijing PLA / Medical Oncology Dept.
-
Fengtai District, Beijing, China, 100071
- 307 Hospital of PLA/Department of Lung Cancer
-
Haidian District, Beijing, China, 100142
- Beijing Cancer Hospital, Department of Thoracic Oncology
-
Haidian District, Beijing, China, 100853
- Chinese PLA General Hospital
-
Tongzhou District, Beijing, China
- Beijing Chest Hospital
-
-
Chongqing
-
Shapingba District, Chongqing, China, 400038
- Respiration department,the First Affiliated Hospital of Third Military Medical University, PLA
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Fujian Province Oncology Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Guangdong General Hospital
-
Guangzhou, Guangdong, China, 510060
- Sun Yat-sen University Cancer Center
-
Guangzhou, Guangdong, China, 510120
- The First Affiliated Hospital of Guangzhou Medical College
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Hunan Provincial Tumor Hospital/Division of Oncology
-
-
Jilin
-
Changchun, Jilin, China
- Department of Oncology, Jilin Provincial Cancer Hospital
-
-
Shandong
-
Qingdao, Shandong, China, 266101
- The affiliated hospital of medical college Qingdao University / Medical oncology department
-
-
Shanghai
-
Shanghai, Shanghai, China, 200433
- Shanghai Pulmonary Hospital
-
Shanghai, Shanghai, China, 200030
- Department of Pulmonary Medicine, Shanghai Chest Hospital
-
Shanghai, Shanghai, China, 200030
- Shanghai Chest Hospital/Lung cancer clinical center
-
Xuhui District, Shanghai, China, 200032
- Zhongshan Hospital Fudan University / Respiratory Department
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Sichuan Province Cancer Hospital/Department of Pulmonary Tumor
-
Chengdu, Sichuan, China, 610041
- Oncology Department, West China Hospital of Sichuan University
-
-
Tianjin
-
Hexi District, Tianjin, China, 300060
- Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Zhejiang Cancer Hospital
-
Hangzhou, Zhejiang, China, 310016
- Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology
-
Hangzhou, Zhejiang, China, 310003
- The First Affiliated Hospital of College of Medicine, Zhejiang University
-
-
-
-
-
Aichi, Japan
- Aichi Cancer Center Hospital
-
Chiba, Japan
- National Cancer Center Hospital East
-
Ehime, Japan
- NHO Shikoku Cancer Center
-
Fukuoka, Japan
- NHO Kyushu Cancer Center
-
Hyogo, Japan
- Hyogo Cancer Center
-
Miyagi, Japan
- Tohoku University Hospital
-
Osaka, Japan
- Osaka City General Hospital
-
Osaka, Japan
- Kinki University Hospital
-
Tokyo, Japan
- National Cancer Center Hospital
-
Tokyo, Japan
- Cancer Institute Hospital of JFCR
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Japan, 411-8777
- Shizuoka Cancer Center
-
-
-
-
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
Seoul, Korea, Republic of
- Asan Medical Center
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
Seoul, Korea, Republic of
- Yonsei University, Severance Hospital
-
-
-
-
-
Taichung, Taiwan
- Taichung Veterans General Hospital
-
Tainan, Taiwan
- National Cheng Kung University Hospital
-
Taipei, Taiwan
- National Taiwan University Hospital
-
Taipei, Taiwan
- Taipei Veterans General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically or cytologically proven diagnosis of NSCLC that is locally advanced or metastatic
- treatment-naïve or have received no more than 3 systemic treatment regimen(s)
- Positive for translocation or inversion events involving the ROS1 gene
- Negative for translocation or inversion events involving the ALK gene
- Patients with brain metastases are eligible if asymptomatic, or if treated, must be neurologically stable for at least 2 weeks and are not taking any contraindicated medications
- Any prior treatment (chemotherapy, radiation [except for palliative], or surgery) must have been completed at least 2 weeks prior to initiation of study medication
- At least 1 measurable tumor lesion as per RECIST v1.1
- Female or male, 18 years of age or older
- ECOG performance status 0 to 1
- Adequate organ function
- Signed and dated informed consent
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, including completion of the PRO measures
- Agree to use effective contraception during the study period and for at least 90 days after completion of the study treatment
Exclusion Criteria:
- Current treatment on another therapeutic clinical trial
- Prior therapy specifically directed against ALK or ROS1 fusion genes
- Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function, carcinomatous meningitis, or leptomeningeal disease
- known interstitial fibrosis or interstitial lung disease
- myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack within 3 months prior to start of study treatment
- Ongoing cardiac dysrhythmias of NCI CTCAE v4.03 Grade >/=2, uncontrolled atrial fibrillation of any grade, or QTc >470 msec
- Pregnant or breast feeding
- Use of drugs or foods that are known potent CYP3A4 inhibitors or inducers
- Use of other anti-cancer drugs including traditional Chinese medicine on the SFDA list
- Evidence of active malignancy within last 3 years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Crizotinib
Single-arm trial whereby all consented, enrolled, eligible patients receive crizotinib
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Independent Radiology Reviewed Overall Objective Response (ORR)
Time Frame: Starting from the first dose study treatment until the first documented CR or PR (every 8 weeks then after 8 cycles at every 12 weeks in duration of 94.0 weeks)
|
Overall objective response (ORR) was defined as the number of patients with a best overall response of confirmed Complete Response or confirmed Partial Response according to RECIST v1.1 (as determined by Independent Radiology Review [IRR]), relative to the total population of response-evaluable participants.
Per RECIST v1.1, CR: disappearance of all target lesions.
Disappearance of all non-target lesions and normalization of tumor marker level.
All lymph nodes must be non-pathological in size (<10 mm short axis); PR: at least 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters.
Confirmed responses were those that persisted on repeat imaging at least 4 weeks after the initial documentation of response.
|
Starting from the first dose study treatment until the first documented CR or PR (every 8 weeks then after 8 cycles at every 12 weeks in duration of 94.0 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IRR-Assessed Duration of Response (DR)
Time Frame: From first documentation of objective tumor response to first documentation of objective PD or death due to any cause, whichever occurred first (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)
|
DR: time from first documentation of objective tumor response (CR or PR) to first documentation of objective progressive disease (PD) or to death due to any cause, whichever occurred first.
If no progression or death on study was observed, or given antitumor treatment other than study drug, participants were censored on date of last on-study tumor assessment.
RECIST v1.1, a) PD: >=20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study), sum must also demonstrate an absolute increase of >=5 mm, appearance of 1 or more new lesions, unequivocal progression of existing non-target lesions; b) CR: disappearance of all target lesions.
Disappearance of all non-target lesions and normalization of tumor marker level.
All lymph nodes must be non-pathological in size (<10 mm short axis); c) PR: >=30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters.
|
From first documentation of objective tumor response to first documentation of objective PD or death due to any cause, whichever occurred first (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)
|
IRR-Assessed Time to Tumor Response (TTR)
Time Frame: From date of first dose of crizotinib to first documentation of objective response was observed (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)
|
TTR was defined as the time from the date of first dose to first documentation of objective tumor response (CR or PR), that was subsequently confirmed.
For participants proceeding from PR to CR, the onset of PR was taken as the onset of response.
RECIST v1.1 (as determined by IRR), a) CR: disappearance of all target lesions.
Disappearance of all non-target lesions and normalization of tumor marker level.
All lymph nodes must be non-pathological in size (<10 mm short axis); b) PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
|
From date of first dose of crizotinib to first documentation of objective response was observed (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)
|
IRR Assessed Disease Control Rate (DCR) at 8 Weeks
Time Frame: At 8 weeks after the start of study treatment
|
DCR at 8 weeks was defined as the percentage of participants with a confirmed CR, confirmed PR, or stable disease (SD) at 8 weeks, respectively, relative to the total population of response evaluable participants.
RECIST v1.1 (as determined by IRR), a) CR: disappearance of all target lesions.
Disappearance of all non-target lesions and normalization of tumor marker level.
All lymph nodes must be non-pathological in size (<10 mm short axis); b) PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
|
At 8 weeks after the start of study treatment
|
IRR-Assessed Progression Free Survival (PFS)
Time Frame: From the date of first dose of crizotinib until the first documentation of objective PD or death (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)
|
PFS was defined as the time from the date of the first dose of crizotinib to first documentation of objective PD or to death on study due to any cause, whichever occurred first.
If no progression or death on study was observed, or given antitumor treatment other than study drug, participants were censored on date of last on-study tumor assessment.
RECIST v1.1, PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
The appearance of one or more new lesions is also considered a sign of progression.
Unequivocal progression of existing non-target lesions.
|
From the date of first dose of crizotinib until the first documentation of objective PD or death (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)
|
Overall Survival (OS)
Time Frame: From date of the first dose of crizotinib until the date of death from any cause (up to 291.9 weeks)
|
OS was defined as the time from the date of the first dose of crizotinib to the date of death due to any cause.
For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive.
|
From date of the first dose of crizotinib until the date of death from any cause (up to 291.9 weeks)
|
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs, Treatment Emergent Treatment Related AEs and SAEs, Grade 3 or 4 Treatment Emergent AEs and Grade 3 or 4 Treatment Emergent Treatment Related AEs
Time Frame: Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)
|
Treatment-emergent AEs :between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Relatedness to crizotinib was assessed by the investigator.
Treatment-related AE: any untoward medical occurrence attributed to study drug in a participant who received study drug.
Serious adverse event (SAE):an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment.
Grade 4 (Life-threatening) events caused participant to be in imminent danger of death.
|
Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)
|
Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4
Time Frame: Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)
|
Laboratory values included hemoglobin increased, anemia, platelet count decreased, leukocytosis, white blood cell decreased, lymphocyte count increased, lymphocyte count decreased and neutrophil count decreased.
Laboratory values were defined as National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) grade 3 or higher.
|
Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)
|
Number of Participants With a Shift of Chemistry Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4
Time Frame: Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)
|
Laboratory values included blood bilirubin increased, alanine aminotransferase increased, aspartate aminotransferase increased, alkaline phosphatase increased, hypoalbuminemia, hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypercalcemia, hypocalcemia, hypophosphatemia, Creatinine increased, hyperuricemia, hypermagnesemia, hypomagnesemia, hyperglycemia and hypoglycemia.
Laboratory values were defined as National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) grade 3 or higher.
|
Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)
|
Change From Baseline to Cycle 60 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) Questionnaire Core 30 (QLQ-C30) Scores
Time Frame: Baseline up to Cycle 60
|
The EORTC QLQ-C30 consists of 30 questions which are incorporated into 5 functional domains (physical, role, cognitive, emotional, and social); a global health status/global QOL scale; 3 symptom scales (fatigue, pain, nausea and vomiting scales); and 6 single items that assess the additional symptoms (dyspnea, appetite loss, sleep disturbance/insomnia, constipation, and diarrhea) and the perceived financial burden of treatment.
All the scales and single-item scores ranged from 0 to 100, higher score is indicative of a higher response level (high score for a functional scale represents a high / healthy level of functioning; high score for the global health status / QoL represents a high QoL; a high score for a symptom scale / item represents a high level of symptomatology / problems).
|
Baseline up to Cycle 60
|
Change From Baseline to Cycle 60 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Lung Cancer Module 13 Scores
Time Frame: Baseline up to Cycle 60
|
The EORTC QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed specific symptoms (dyspnea, cough, hemoptysis, and site-specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia).
Scores on each scale and item ranged from 0 to 100, higher score is indicative of a higher response level (a high score for a symptom scale / item represents a high level of symptomatology / problems).
|
Baseline up to Cycle 60
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 30, 2013
Primary Completion (ACTUAL)
July 31, 2015
Study Completion (ACTUAL)
January 22, 2020
Study Registration Dates
First Submitted
September 5, 2013
First Submitted That Met QC Criteria
September 13, 2013
First Posted (ESTIMATE)
September 18, 2013
Study Record Updates
Last Update Posted (ACTUAL)
February 21, 2021
Last Update Submitted That Met QC Criteria
February 3, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Crizotinib
Other Study ID Numbers
- OO 12-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Genelux CorporationNewsoara Biopharma Co., Ltd.Not yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Advanced Non-squamous Non-small-cell Lung Cancer | Non-small Cell Lung Cancer Stage IV | Metastatic Squamous Non-Small Cell Lung Carcinoma | Non-small Cell Lung Cancer Recurrent | Metastatic Non-squamous Non Small Cell Lung Cancer and other conditions
Clinical Trials on Crizotinib
-
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...Not yet recruitingNon-Small Cell Lung CancerUnited States
-
PfizerWithdrawnCarcinoma, Renal Cell | Glioblastoma | Carcinoma, Hepatocellular
-
Samsung Medical CenterCompletedc-MET Positive Gastric CancerKorea, Republic of
-
PfizerCompletedRenal ImpairmentUnited States
-
PfizerCompleted
-
PfizerCompletedHealthy VolunteerUnited States
-
European Organisation for Research and Treatment...PfizerCompletedLocally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma | Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor | Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1 | Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma | Locally Advanced... and other conditionsFrance, Belgium, Netherlands, Germany, United Kingdom, Italy, Norway, Poland, Slovakia, Slovenia
-
PfizerCompleted